Pancreatic Adenocarcinoma, Version 1.2019 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Tempero, M. A., Malafa, M. P., Chiorean, E., Czito, B., Scaife, C., Narang, A. K., Fountzilas, C., Wolpin, B. M., Al-Hawary, M., Asbun, H., Behrman, S. W., Benson, A. B., Binder, E., Cardin, D. B., Cha, C., Chung, V., Dillhoff, M., Dotan, E., Ferrone, C. R., Fisher, G., Hardacre, J., Hawkins, W. G., Ko, A. H., LoConte, N., Lowy, A. M., Moravek, C., Nakakura, E. K., O'Reilly, E. M., Obando, J., Reddy, S., Thayer, S., Wolff, R. A., Burns, J. L., Zuccarino-Catania, G. 2019; 17 (3): 203–10

Abstract

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights discuss important updates to the 2019 version of the guidelines, focusing on postoperative adjuvant treatment of patients with pancreatic cancers.

View details for PubMedID 30865919